文献速递生殖医学

比较两种来源不同HCG、获得LH生物活性的HMG制剂疗效与安全性的随机对照试验

A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources.
PubMed 文献 · Reprod Biomed Online · 2017-04-20

这项前瞻性、对照、随机、多中心、非劣效性研究比较了两种HMG制剂(Menopur®-Ferring与Meriofert®-IBSA)在270例18至39岁、BMI≤30 kg/m2、既往完成辅助生殖技术周期少于3次的IVF女性中的卵巢刺激效果。采用标准长方案GnRH激动剂降调节及HCG触发,主要终点为获卵总数。两组多数临床显著终点无统计学显著差异,新HMG组获卵总数高于对照(11.6±6.6 vs 9.7±5.9,差值95%CI +0.43至+3.43),OHSS发生频率安全性特征相同。

要点

  • 新HMG组获卵总数11.6±6.6枚,对照HMG组9.7±5.9枚,差值95%CI为+0.43至+3.43。
  • 两组胚胎质量、受精率、种植率、持续妊娠率及活产率无统计学显著差异。
  • 新HMG组通过更短的刺激获得更多卵母细胞,但每获卵所需的HMG单位数相当。

核心结论

  • 新HMG制剂是IVF周期卵巢刺激的可行替代方案。

研究设计与样本

  • 前瞻性、对照、随机、多中心、非劣效性研究,纳入270例接受IVF的18至39岁女性,BMI≤30 kg/m2,既往完成辅助生殖技术周期少于3次。
  • 采用标准长方案GnRH激动剂降调节及HCG触发,主要终点为获卵总数。

主要发现

  • 两组多数临床显著终点无统计学显著差异,包括胚胎质量、受精率、种植率、持续妊娠率和活产率。
  • 新HMG组获卵总数高于对照HMG组,分别为11.6±6.6与9.7±5.9,差值95%CI为+0.43至+3.43。
  • 新HMG组通过更短的刺激获得更多卵母细胞,但每获卵所需的HMG单位数相当。
  • 两组卵巢过度刺激综合征发生频率的安全性特征相同。

关键数值与推荐

  • 新HMG组获卵总数11.6±6.6枚,对照HMG组9.7±5.9枚,差值95%CI +0.43至+3.43。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur®- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Lockwood G, Cometti B, Bogstad J, et al. A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources. Reprod Biomed Online. 2017. PMID: 28476487. doi:10.1016/j.rbmo.2017.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。